Serum CK levels and thymoma-associated autoantibody levels in patients with thymoma before and after avelumab treatment
| Patient | Serum CK (IU/L) | Anti-AChR (nmol/L) | Anti-STR (dilutions) | Anti-VGKC (nmol/L) | Anti-GAD65 (nmol/L) | Anti-α3 (nmol/L) | Anti-CRMP5 | Anti-AMPAR | Anti-GABABR | Anti-NMDA | Anti-LGI1 | Anti-Caspr2 |
| #1 Pre | 55 | 2.59 | 3840 | 0 | NT | 0 | Neg | Neg | Neg | Neg | Neg | Neg |
| #1 Day 15 post | 1792 | 2.36 | 1920 | 0 | 0.02 | 0 | Neg | Neg | Neg | Neg | Neg | Neg |
| #2 Pre | 86 | 0.21 | Neg | 0 | 0 | 0 | Neg | Neg | Neg | Neg | Neg | Neg |
| #2 Day 43 post | 1046 | 0.24 | Neg | 0 | 0 | 0 | Neg | Neg | Neg | Neg | Neg | Neg |
| #3 Pre | 130 | 0.36 | 7680 | 0 | 0 | 0 | Neg | Neg | Neg | Neg | Neg | Neg |
| #3 Day 15 post | 3939 | 0.31 | 7680 | 0 | 0 | 0 | Neg | Neg | Neg | Neg | Neg | Neg |
| #4 Pre | 77 | 0 | Neg | 0 | 0 | 0 | Neg | Neg | Neg | Neg | Neg | Neg |
| #4 Day 15 post | 60 | 0 | Neg | 0 | 0 | 0 | Neg | Neg | Neg | Neg | Neg | Neg |
| #5 Pre | 435 | 0 | Neg | 0.11 | 0 | 0 | Neg | Neg | Neg | Neg | Neg | Neg |
| #5 Day 15 post | 473 | 0 | Neg | 0.15 | 0 | 0 | Neg | Neg | Neg | Neg | Neg | Neg |
| #6 Pre | 91 | 0.73 | 30 720 | 0.06 | 0 | 0 | Neg | Neg | Neg | Neg | Pos | Neg |
| #6 Day 8 post | 762 | 0.67 | 61 440 | 0.01 | 0 | 0 | Neg | Neg | Neg | Neg | Pos | Neg |
| #7 Pre | 87 | 0 | Neg | 0 | 0 | 0 | Neg | Neg | Neg | Neg | Neg | Neg |
| #7 Day 15 | 74 | 0 | Neg | 0 | 0 | 0 | Neg | Neg | Neg | Neg | Neg | Neg |
| #8 Pre | 45 | 0 | Neg | 0 | 0 | 0 | Neg | Neg | Neg | Neg | Neg | Neg |
| #8 Day 15 | 28 | 0 | Neg | 0 | 0 | 0 | Neg | Neg | Neg | Neg | Neg | Neg |
Note that serum CK levels included in this table are those obtained at the time sera were collected for autoantibody testing and may not reflect peak CK levels for a given patient. Autoantibody testing was performed at the Neuroimmunology Laboratory, Mayo Clinic, Rochester, Minnesota.
α3, ganglionic α3 acetylcholine receptor; AChR, acetylcholine receptor; AMPAR, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor; Caspr2, contactin-associated protein-like 2; CK, creatine kinase; CRMP5, collapsin response-mediator protein-5; GABAR, gamma-aminobutyric acid receptor; GAD65, glutamic acid decarboxylase 65; LGI1, leucine-rich glioma-inactivated 1; Neg, negative; NMDA, N-methyl-D-aspartate receptor; NT, not tested; Pos, positive; STR, striational; VGKC, voltage -gated potassium channel.